Mumbai: Tata Consultancy Services (TCS) has partnered with Dassault Systems through its Living Heart Project that unites an ecosystem of cardiovascular researchers, educators, medical device developers, regulatory agencies including the US FDA, and practising cardiologists, to develop and validate realistic digital simulations of the human heart.
The project will create groundbreaking medical solutions, including the use of heart simulation as a source of digital evidence for new cardiovascular device approvals. This includes an in-silico clinical trial that could complement the evidence drawn from clinical subjects while reducing the need for animal testing and human enrollment for clinical trials.
As an industry partner, TCS will use its domain and technology expertise, and its research on the Digital BioTwin of the heart to contribute to model refinement, simulation, and technological implementation in developing and validating highly accurate, personalised digital human heart models.
The TCS Digital BioTwin is a biophysics-based high-fidelity computational model developed by TCS researchers, to enable the investigation of the function of a particular human organ remotely and non-invasively. It helps in understanding the individual contributions of several factors and analyses their interactions at a spatial scale. The company has been conducting extensive research in building digital bio-twins of organs such as skin, nose, and colon. To complement this research, TCS will also collaborate with Dassault Systems and others towards the goal of a Virtual Human Twin, with a focus on select organs identified as critical for the advancement of the field.
“We are delighted to welcome Tata Consultancy Services to our Living Heart Project,” said Steve Levine, Sr Director, Virtual Human Modeling, Dassault Systèmes and Founder, The Living Heart Project, “By joining forces, we believe we can accelerate the pace of innovation and make significant strides towards our goal of creating and delivering personalised in-silico medical solutions.”
“TCS is excited to be a part of the Living Heart initiative, and to collaborate in creating a pathbreaking digital simulation of the human heart that can enrich our understanding of the cardiac function and provide insights for novel cardiac treatments and new product development for the med-tech and pharma sectors. We believe that our extensive expertise in building digital bio-twins for other organs and body parts positions us well to contribute significantly to this collaborative initiative,” said Vikram Karakoti, Global Head, Life Sciences Business, TCS.